Clinical trial NCT00824343: A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer
Official title: An Open Label, Multicenter Phase II Study to Evaluate Efficacy and Safety of P276-00 in Indian Subjects With Recurrent, Metastatic or Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Squamous Cell Carcinoma of Head and Neck
Lead sponsor: Piramal Enterprises Limited
Sponsor class: INDUSTRY
First posted: 2009-01-16
Enrollment: 86
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a single arm phase II trial to study the efficacy and safety of a Cdk inhibitor P276-00 in the treatment of squamous cell carcinoma of head and neck. Patients with recurrent or metastatic disease that is unresectable and incurable by radiation will be enrolled. Thirty eight evaluable patients need to be enrolled in the study. All patients will receive protocol treatment i.e. P276-00 as an intravenous infusion from day 1 to day 5 and from day 8 to day 12 in each 21 day cycle till progression of disease or unacceptable toxicity. Safety evaluations by means of recording vitals, physical examination and lab investigations like hematology and clinical chemistry will be undertaken at regular intervals in each cycle. Tumor measurements by spiral CT scan will be undertaken at baseline and at the end of every 2 cycles for response evaluation by RECIST criteria. All patients will be followed up for survival status till one year of cycle 1 day 1.

Detailed description: P276-00 was administered at a dose of 185mg/m2/day from day 1 to day 5 in each 21 day cycle. The protocol was amended in July 2009. As per the amendment P276-00 will be administered at a dose of 144 mg/m2/day from day 1 to day 5 and from day 8 to day 12 in each 21 day cycle till progression of disease or unacceptable toxicity.33 patients have been recruited in version 1 protocol, 38 more evaluable patients need to be recruited in version 2 protocol. Allowing for approximately 30% drop-outs, it is estimated that, for enrolling 38 evaluable subjects in the study, approximately 54 subjects would be enrolled. As the study has already enrolled 33 subjects, the sample size for the study to accommodate for same number of subjects (38 evaluable) in the revised protocol is estimated as approximately 87 (33 + 54) subjects. Hence the total sample size (accounting for drop-outs) is 87 patients.

Eligibility criteria: Inclusion Criteria:

1. Age more than or equal to 18 years
2. Subjects with histologically or cytologically confirmed SCCHN that is recurrent and/or metastatic and judged incurable by surgery and/or radiation therapy and with zero to one line of chemotherapy for recurrent or metastatic disease at least 60 days prior to study entry.
3. Measurable disease, defined as at least one unidimensionally measurable lesion ≥ 20 mm by conventional techniques or ≥10 mm by spiral computerized tomography (CT) scan or magnetic resonance imaging (MRI)
4. Tumor that is accessible to biopsy
5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
6. Life expectancy of at least three months
7. Hemoglobin ≥ 8.0 gm/dL
8. Absolute neutrophil count (ANC) ≥ 1000/mm3
9. Platelet count ≥ 50,000/mm3
10. Total bilirubin ≤1.5X institutional upper limit of normal (ULN)
11. Serum AST ≤ 3X institutional ULN
12. Serum ALT ≤ 3X institutional ULN
13. Serum creatinine ≤1.5X institutional ULN
14. Ability to understand and the willingness to sign a written informed consent document (ICD)

Exclusion Criteria:

1. Nasopharyngeal carcinoma
2. Prior treatment with P276-00 or other Cyclin dependent kinase (CDK) targeting agents
3. History of allergic reactions attributed to compounds of similar chemical composition to P276-00
4. Subjects who have received radiotherapy, chemotherapy or biologic/targeted anticancer agents within 60 days prior to Day 1 of study drug administration or have not recovered from adverse effects of any prior radiotherapy, chemotherapy or biologic/targeted agents.
5. More than one chemotherapy regimen for the recurrent or metastatic disease
6. Subjects who had received any other investigational drug within 1 month or within five half-lives of the other investigational agent, whichever is longer prior to Day 1 of study drug administration
7. Subjects with QTc \> 450 msec on 12 lead standard electrocardiogram (ECG)
8. History of unstable angina or myocardial infarction or stroke within previous 6 months
9. Subjects with uncontrolled inter-current illness including, but not limited to active infection, symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
10. Subjects known to be suffering from infection with HIV, Tuberculosis, Hepatitis C or Hepatitis B
11. Known brain metastasis
12. History of prior malignancy except for curatively treated basal cell or squamous cell carcinoma of skin, in situ cervical cancer, in situ breast cancer, in situ prostate cancer or any other cancer for which the subject has been disease-free for at least 3 years
13. Women who are pregnant or lactating
14. Women of childbearing potential \[defined as sexually mature women who have not undergone hysterectomy or who have not been naturally postmenopausal for at least 24 consecutive months (i.e. who have had menses any time in the preceding 24 consecutive months)\] and men, not agreeing to use adequate contraception (e.g., hormonal or barrier method of birth control or abstinence) prior to study entry (after signing the ICD), during the period of study participation and for at least 4 weeks after withdrawal from the study, unless they are surgically sterilized
15. Any condition, including laboratory abnormalities, that in the opinion of the Investigator places the subject at an unacceptable risk or deems the subject not suitable for participation in the study

Primary outcomes:
measure: Response rate
timeFrame: Tumor measurements to be undertaken at baseline and at the end of every 2 cycles. Response evaluation to be performed on the basis of RECIST criteria
Secondary outcomes:
measure: Duration of response, Progression free survival (PFS), Time to progression (TTP), PFS at one year, Overall survival (OS) at one year
timeFrame: Tumor measurements at the end of every 2 cycles. Follow up for survival status every 4 weeks after discontinuation of protocol treatment till one year of cycle 1 day 1
Other outcomes:
Locations:
city: Mysore
country: India
facility: Bharath Hospital & Institute of Oncology, Mysore
state: Karnataka
city: Trivandrum
country: India
facility: Regional Cancer Centre
state: Kerala
city: Mumbai
country: India
facility: Kashyap Nursing Home
state: Maharashtra
city: Mumbai
country: India
facility: Jaslok Hospital, Mumbai
state: Maharashtra
city: Nagpur
country: India
facility: Central India Cancer Research Institute,
state: Maharashtra
city: Pune
country: India
facility: Deenanath Mangeshkar Hospital & Research Centre
state: Maharashtra
city: Jaipur
country: India
facility: Bhagwan Mahaveer Cancer Hospital & Research Centre, Dept. Of Medical Oncology, Jaipur
state: Rajasthan
city: Coimbatore
country: India
facility: V. N. Cancer Centre, GKNM Hospital,
state: Tamilnadu
city: Lucknow
country: India
facility: Dept. Of Surgical Oncology, CSM Medical University, Lucknow
state: UttarPradesh
Study officials:
affiliation: Director and Onco-Surgeon, Central India Cancer Research Institute, Nagpur
name: Dr. Ajay Mehta
role: PRINCIPAL_INVESTIGATOR
affiliation: Radiation Oncologist, Bharat Hospital Institute of Oncology, Mysore
name: Dr. M S Vishveshwara
role: PRINCIPAL_INVESTIGATOR
affiliation: Oncosurgeon, Department of Surgical Oncology, CSM Medical University, Lucknow
name: Dr. Sanjeev Misra
role: PRINCIPAL_INVESTIGATOR
affiliation: Associate Professor, Regional Cancer Centre, Trivandram
name: Dr. Rejnish Kumar
role: PRINCIPAL_INVESTIGATOR
affiliation: Consultant Medical Oncologist, Bhagwan Mahavir Cancer Hospital and Research Centre, Jaipur
name: Dr. Lalit Mohan Sharma
role: PRINCIPAL_INVESTIGATOR
affiliation: Medical Oncologist, Jaslok Hospital, Mumbai
name: Dr. Maheboob Basade
role: PRINCIPAL_INVESTIGATOR
affiliation: Medical Oncologist
name: Dr. Nilesh Lokeshwar, MD, DM
role: PRINCIPAL_INVESTIGATOR
affiliation: Medical Oncologist, Deenanath Mangeshkar Hospital and Research Centre, Pune, India
name: Dr. Chetan Deshmukh, MD, DM
role: PRINCIPAL_INVESTIGATOR
affiliation: Radiation Oncologist, V. N. Cancer Centre, GKNM Hospital, Coimbatore, India
name: Dr. M Nagarajan, MD
role: PRINCIPAL_INVESTIGATOR
References: